<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581607</url>
  </required_header>
  <id_info>
    <org_study_id>BOSAPAH-1</org_study_id>
    <secondary_id>7-3-22-1</secondary_id>
    <nct_id>NCT00581607</nct_id>
  </id_info>
  <brief_title>Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension</brief_title>
  <acronym>BOSAPAH</acronym>
  <official_title>Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with advanced sarcoidosis often develop pulmonary hypertension. Pulmonary&#xD;
      hypertension is a condition where the right side of the heart has to push the blood though&#xD;
      the lungs at a higher pressure than normal. Since this pressure is higher, it is harder for&#xD;
      the heart to pump the blood through the lungs to the left side of the body. If the blood can&#xD;
      not get through the lungs, it can not get pumped through the rest of the body. This leads to&#xD;
      weakness and shortness of breath. This type of hypertension does not usually respond to&#xD;
      regular blood pressure medicines. The purpose of this study is to determine if bosentan&#xD;
      (Tracleer) will help sarcoidosis associated pulmonary hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized in 2:1 manner to receive either bosentan or placebo for 16 weeks.&#xD;
      After 16 weeks, there will be an additional 32 weeks of an open label extension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in six minute walk distance</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary hemodynamics</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life with therapy</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Bosentan for 16 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>62.5 mg bid for 4 weeks, then 125 mg bid</description>
    <arm_group_label>Bosentan for 16 weeks</arm_group_label>
    <other_name>Tracleer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>drug given for 16 weeks</description>
    <arm_group_label>Bosentan for 16 weeks</arm_group_label>
    <other_name>tracleer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with known sarcoidosis 21.&#xD;
&#xD;
          -  Age 18 or greater&#xD;
&#xD;
          -  Patients with documented pulmonary hypertension with a PA mean &gt; 25 mm Hg as measured&#xD;
             by cardiac catheterization within six months of entry into the study. Pulmonary artery&#xD;
             occluding pressure and or left ventricular end diastolic pressure must be less than 15&#xD;
             mm Hg.&#xD;
&#xD;
          -  Patients with WHO class II or III&#xD;
&#xD;
          -  Six minute walk distance of between 100 to 500 meters&#xD;
&#xD;
          -  Patients on stable immunotherapy for their sarcoidosis, including prednisone,&#xD;
             methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or&#xD;
             infliximab&#xD;
&#xD;
          -  Patients able to provide written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) n&#xD;
             the prior 28 days. Patients on stable dose of calcium channel blocker for more than 1&#xD;
             month prior to right heart catheterization can be continued on the calcium channel&#xD;
             blocker.&#xD;
&#xD;
          -  Patients with severe airway obstruction as defined by FEV1/FVC of less than 35%&#xD;
&#xD;
          -  Patients with World Health Organization (WHO) class IV status.&#xD;
&#xD;
          -  Patients who are pregnant or breast feeding&#xD;
&#xD;
          -  Patients with significant left ventricular dysfunction with a left ventricular&#xD;
             ejection fraction of less than 35%&#xD;
&#xD;
          -  Cardiac index &lt; 2.0 liters and/or right atrial pressure &gt;15 mm Hg&#xD;
&#xD;
          -  Significant liver dysfunction not due to sarcoidosis.&#xD;
&#xD;
          -  Patients with severe other organ disease felt by investigators to impact on survival&#xD;
             during the course of the study.&#xD;
&#xD;
          -  Patients unable to perform the 6 minute walk study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P Baughman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2007</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Robert P Baughman</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Sarcoidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 30, 2018</submitted>
    <returned>February 27, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

